If this is where you are
Newly diagnosedReports arriving, no plan yetAlready tested elsewhereYou have results you cannot readOn treatment nowYou want to know it is workingOr
Finished treatmentWatching for anything left behindWorried about familyInherited risk, and relativesWanting a second opinionA decision you are unsure aboutDecide
Blueprint CareThe flagship decision report and a dedicated clinical teamSignalOne free question answered on WhatsApp within four hoursNavigationRecords you already have, turned into a clarity timelineDecipherInterpretation of sequencing already done elsewhereTest
Signature, all tiersSolid tumour and blood cancer panels comparedSignature STb33 genes from a blood drawSignature STb O118 genes from a blood drawSignature STb O+523 genes, with TMB and MSISignature STt OProfiling from an existing tissue blockMonitor
SentinelSerial monitoring while treatment is runningSentinel SolidctDNA monitoring for solid tumoursClearMolecular residual disease surveillanceClear SolidTumour-informed surveillanceProtect
HeritageInherited risk, assessed properlyHeritage CoreA broad inherited-risk assessmentHeritage AdhocFocused testing for named relativesCancer DictionaryWhat is discussed in your specific cancerReference
Cancer DictionaryOne structured entry per cancer typeBiomarker LibraryOne page per marker, in plain languagePatient ResourcesGlossary, guides and how to use themWatch, read and ask
Video LibraryShort explainers, captioned and translatedStoriesPatient and clinician experiences, consentedFAQThe questions we are asked mostCancer Dictionary · Head, neck and thyroid
Nasopharyngeal carcinoma is biologically and epidemiologically distinct from other head and neck cancers. Epstein-Barr virus is central to its development, and circulating EBV DNA is one of the most established blood-based tumour markers in solid oncology, used in screening, prognosis and monitoring.
Also called NPC.
Start here
Nasopharyngeal carcinoma is defined by its association with Epstein-Barr virus, which makes the virus itself both the diagnostic clue and the most useful thing to measure over time.
Nasopharyngeal carcinoma is biologically and epidemiologically distinct from other head and neck cancers. Epstein-Barr virus is central to its development, and circulating EBV DNA is one of the most established blood-based tumour markers in solid oncology, used in screening, prognosis and monitoring.
01Before any molecular question
Usually established first: histological subtype, stage, and EBV status. Because the nasopharynx is difficult to examine, presentation is often through a neck lump or through ear or nasal symptoms rather than through a visible primary.
Usually already established
02
The divisions below are not labels. Each one changes what the treatment discussion is actually about.
Keratinising squamous cell carcinoma
Less strongly EBV-associated, and more similar to other head and neck squamous cancers.
Non-keratinising carcinoma
The predominant EBV-associated type in endemic regions.
Locally advanced disease
Where chemoradiation organises the discussion. Most patients present at this stage.
Recurrent or metastatic disease
Where systemic treatment, immune approaches and trial options come into the discussion.
03What is discussed
Epstein-Barr virus is present in tumour cells in the endemic non-keratinising form. Common genomic alterations include CDKN2A loss, TP53 alteration, and alterations in NF-kB pathway genes. PD-L1 expression is frequently high, and the disease is generally considered immunologically active. Comprehensive genomic profiling is less often decisive than the viral measurement, which is unusual: the most useful molecular test in this cancer measures the virus rather than the tumour genome.
EBV DNA
Circulating viral DNA. One of the most established blood-based tumour markers in solid oncology.
PD-L1
Frequently high. Part of the immune treatment discussion.
TMB
Generally low to moderate despite immune responsiveness.
CDKN2A
Commonly lost. Descriptive rather than actionable.
This is not an exhaustive list, and which markers are relevant depends on the individual case. Not every marker listed is assessed in every patient.
04What is tested, and from what
Circulating EBV DNA measurement is the distinctive test in this disease, used before treatment as a prognostic marker, during treatment to assess response, and afterwards for surveillance. Comprehensive genomic profiling is discussed in recurrent or metastatic disease, primarily for trial access.
Familial clustering is described in endemic regions, and both genetic and environmental factors are thought to contribute. No single high-penetrance gene explains most cases, and formal germline testing is not a routine part of the pathway. Screening of relatives using EBV serology and circulating EBV DNA has been studied in endemic populations.
Cancer genetics and hereditary riskCirculating EBV DNA is the established measurement here, and it is a genuinely useful example of a circulating marker changing practice: it has been studied for population screening in endemic regions, is prognostic before treatment, and is used to detect recurrence.
More on ctDNA monitoring05The timing question
Testing that arrives after the decision it was meant to inform has already been made is a common and avoidable problem. This is the sequence in which molecular information tends to become relevant.
06Take these to your team
When a decision is being made
Questions worth raising with a treating team.
At progression, recurrence or resistance
The molecular picture at diagnosis is not always the molecular picture later.
07What shapes eligibility
Trial activity centres on immune approaches, EBV-directed cellular therapies and treatment de-escalation guided by EBV DNA. Circulating EBV DNA level is itself frequently written into eligibility or stratification criteria, which is unusual.
| Term | What it means |
|---|---|
| Epstein-Barr virus | A common virus that most people carry harmlessly, but which is causally linked to this cancer and to some lymphomas. |
| Circulating EBV DNA | Viral DNA measurable in blood, reflecting tumour burden. |
| Endemic | Occurring at a consistently higher rate in a particular population or region. |
| Non-keratinising | The histological type most associated with EBV and with endemic regions. |
These are the services most often relevant to this cancer. Which of them applies is a clinical question, not an automatic one.
This entry is educational. It describes what is commonly discussed in this cancer, not what should happen for any individual. Which of it applies depends on the specific diagnosis, stage, prior treatment and the person themselves. Nothing here is a recommendation, and no list of biomarkers here is exhaustive. Decisions belong with a treating team who know the whole case.
Take the next step
A no-obligation conversation with our care team, arranged through KPCIRC.
Book a consultationCommission your decision report and a dedicated clinical team.
Explore Blueprint CareSignal replies to your first question within four hours, at no cost.
Start with Signal